FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894740407> ?p ?o ?g. }

• W2894740407 endingPage "e0204551" @default.
• W2894740407 startingPage "e0204551" @default.
• W2894740407 abstract "The present study aimed to confirm the efficacy and safety of topical and intravenous tranexamic acid (TXA) compared with that of topical placebo and to assess the noninferiority between the two application methods of TXA in patients undergoing unilateral primary total hip arthroplasty.Our randomized controlled trial investigated 170 patients with 1:1:1 allocation to two doses of 10-mg/kg intravenous TXA, 3-g topical TXA, and topical placebo of 60-ml physiological saline groups. The primary outcome, total blood loss, was calculated with Nadler and Gross formula. The secondary outcomes included allogeneic blood transfusion requirement, drain blood loss, decreased hemoglobin level. Noninferiority would be established when the upper limit 95% CI is lower than 250 ml of the noninferiority margin for the mean difference of total blood loss between topical and intravenous TXA. Thromboembolic complication incidence was considered as a safety outcome.The total blood loss of patients administered intravenous (mean±standard deviation, 1125±514 ml) and topical TXA (1211±425 ml) was significantly reduced compared with that of those administered topical placebo (1464±556 ml) (p = 0.0012). Drain blood loss and hemoglobin level reduction in patients administered with TXA were also significantly lower than those in patients administered topical placebo. The mean difference of total blood loss between topical and intravenous TXA is 86 ml (95% CI, -88 to 260 ml). The complications were comparable between patients managed with TXA and patients with topical placebo.The noninferiority of topical TXA to intravenous TXA can not be concluded. Considering no significant difference was found in all efficacy outcomes between the two administration methods. Any of the two TXA administration methods can be adopted for blood loss prevention in total hip arthroplasty." @default.
• W2894740407 created "2018-10-12" @default.
• W2894740407 creator A5007054845 @default.
• W2894740407 creator A5011783529 @default.
• W2894740407 creator A5022147066 @default.
• W2894740407 creator A5024184162 @default.
• W2894740407 creator A5025301183 @default.
• W2894740407 creator A5049494334 @default.
• W2894740407 date "2018-10-02" @default.
• W2894740407 modified "2023-10-15" @default.
• W2894740407 title "Is topical or intravenous tranexamic acid preferred in total hip arthroplasty? A randomized, controlled, noninferiority clinical trial" @default.
• W2894740407 cites W163835151 @default.
• W2894740407 cites W1849776081 @default.
• W2894740407 cites W1890871020 @default.
• W2894740407 cites W1981196689 @default.
• W2894740407 cites W1981939399 @default.
• W2894740407 cites W1984748046 @default.
• W2894740407 cites W1990694409 @default.
• W2894740407 cites W2010243313 @default.
• W2894740407 cites W2035980026 @default.
• W2894740407 cites W2036468563 @default.
• W2894740407 cites W2040538032 @default.
• W2894740407 cites W2041870050 @default.
• W2894740407 cites W2059989187 @default.
• W2894740407 cites W2063161947 @default.
• W2894740407 cites W2065040102 @default.
• W2894740407 cites W2081692561 @default.
• W2894740407 cites W2086064501 @default.
• W2894740407 cites W2086090962 @default.
• W2894740407 cites W2095465279 @default.
• W2894740407 cites W2100730818 @default.
• W2894740407 cites W2101786025 @default.
• W2894740407 cites W2105120454 @default.
• W2894740407 cites W2105699409 @default.
• W2894740407 cites W2126479706 @default.
• W2894740407 cites W2126807843 @default.
• W2894740407 cites W2134099987 @default.
• W2894740407 cites W2156515605 @default.
• W2894740407 cites W2156653052 @default.
• W2894740407 cites W2167976338 @default.
• W2894740407 cites W2170427810 @default.
• W2894740407 cites W2277111537 @default.
• W2894740407 cites W2311747236 @default.
• W2894740407 cites W2430497895 @default.
• W2894740407 cites W2605806871 @default.
• W2894740407 cites W2763737013 @default.
• W2894740407 cites W4238071782 @default.
• W2894740407 cites W50135966 @default.
• W2894740407 cites W63395447 @default.
• W2894740407 doi "https://doi.org/10.1371/journal.pone.0204551" @default.
• W2894740407 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6168126" @default.
• W2894740407 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30278067" @default.
• W2894740407 hasPublicationYear "2018" @default.
• W2894740407 type Work @default.
• W2894740407 sameAs 2894740407 @default.
• W2894740407 citedByCount "10" @default.
• W2894740407 countsByYear W28947404072019 @default.
• W2894740407 countsByYear W28947404072020 @default.
• W2894740407 countsByYear W28947404072021 @default.
• W2894740407 countsByYear W28947404072022 @default.
• W2894740407 countsByYear W28947404072023 @default.
• W2894740407 crossrefType "journal-article" @default.
• W2894740407 hasAuthorship W2894740407A5007054845 @default.
• W2894740407 hasAuthorship W2894740407A5011783529 @default.
• W2894740407 hasAuthorship W2894740407A5022147066 @default.
• W2894740407 hasAuthorship W2894740407A5024184162 @default.
• W2894740407 hasAuthorship W2894740407A5025301183 @default.
• W2894740407 hasAuthorship W2894740407A5049494334 @default.
• W2894740407 hasBestOaLocation W28947404071 @default.
• W2894740407 hasConcept C126322002 @default.
• W2894740407 hasConcept C141071460 @default.
• W2894740407 hasConcept C142724271 @default.
• W2894740407 hasConcept C168563851 @default.
• W2894740407 hasConcept C203092338 @default.
• W2894740407 hasConcept C204787440 @default.
• W2894740407 hasConcept C27081682 @default.
• W2894740407 hasConcept C2778917026 @default.
• W2894740407 hasConcept C2779637338 @default.
• W2894740407 hasConcept C2780014101 @default.
• W2894740407 hasConcept C2991743468 @default.
• W2894740407 hasConcept C42219234 @default.
• W2894740407 hasConcept C71924100 @default.
• W2894740407 hasConceptScore W2894740407C126322002 @default.
• W2894740407 hasConceptScore W2894740407C141071460 @default.
• W2894740407 hasConceptScore W2894740407C142724271 @default.
• W2894740407 hasConceptScore W2894740407C168563851 @default.
• W2894740407 hasConceptScore W2894740407C203092338 @default.
• W2894740407 hasConceptScore W2894740407C204787440 @default.
• W2894740407 hasConceptScore W2894740407C27081682 @default.
• W2894740407 hasConceptScore W2894740407C2778917026 @default.
• W2894740407 hasConceptScore W2894740407C2779637338 @default.
• W2894740407 hasConceptScore W2894740407C2780014101 @default.
• W2894740407 hasConceptScore W2894740407C2991743468 @default.
• W2894740407 hasConceptScore W2894740407C42219234 @default.
• W2894740407 hasConceptScore W2894740407C71924100 @default.
• W2894740407 hasIssue "10" @default.
• W2894740407 hasLocation W28947404071 @default.
• W2894740407 hasLocation W28947404072 @default.

• next